Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Mark Vickery headshot

Top Research Reports for Broadcom, Oracle & Cisco Systems

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Broadcom Inc. (AVGO), Oracle Corporation (ORCL), and Cisco Systems, Inc. (CSCO). as well as a micro-cap stock United-Guardian, Inc. (UG).

Sundeep Ganoria headshot

Will the FDA's Nod for Subcutaneous Keytruda Ease Merck's Headwinds?

by Sundeep Ganoria

FDA clears MRK's Keytruda Qlex, a subcutaneous option that promises faster treatment and new patent protection amid looming headwinds.

Zacks Equity Research

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

In the most recent trading session, Moderna (MRNA) closed at $25.51, indicating a +2.03% shift from the previous trading day.

Zacks Equity Research

MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

by Zacks Equity Research

Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.

Kinjel Shah headshot

Vertex Plunges Around 24% in Six Months: How to Play the Stock

by Kinjel Shah

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Kinjel Shah headshot

Will GSK Be Able to Resolve Its Vaccine Challenges Anytime Soon?

by Kinjel Shah

GSK faces U.S. vaccine sales declines as Shingrix and Arexvy stumble. Penmenvy approval and pipeline efforts may aid long-term growth.

Sundeep Ganoria headshot

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

by Sundeep Ganoria

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

Zacks Equity Research

Moderna (MRNA) Declines More Than Market: Some Information for Investors

by Zacks Equity Research

Moderna (MRNA) reached $23.51 at the closing of the latest trading day, reflecting a -7.4% change compared to its last close.

Kinjel Shah headshot

Merck Falls 14% YTD: Time to Buy, Sell or Hold the Stock?

by Kinjel Shah

Merck stock is down 14% this year as Keytruda-led growth gets offset by Gardasil weakness and looming patent risks, which cloud the outlook.

Zacks Equity Research

Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.